Alleviant Medical Develop Innovative Device To Improve Heart Failure Treatment

Alleviant Medical Develop Innovative Device To Improve Heart Failure Treatment

Congestive heart failure is a major public health problem, affecting over 23 million worldwide. While the global economic burden is not known, it is estimated to cost over $35 billion in the US alone. Existing therapies offer some clinical benefit, but can in many cases be ineffective at relieving symptoms and reduce hospital admissions. Many patients suffer with very limited quality of life, and despite best medical therapy, 50% of all heart failure patients die within 5 years of diagnosis.

The Houston-based startup Alleviant Medical aim to create a paradigm-shift in the treatment of congestive heart failure and is developing a minimally-invasive device that could relieve symptoms and improve functional mobility. The transcatheter device is a single-use disposable that relieves pressure buildup in the left atrium of heart, which is the key driver of heart failure symptoms. It enters the body near the groin and travel through the body to the heart via the femoral vein. An expandable blade then cut a hole in wall separating the left and right atria, and the tissue is pulled back into the device which is then safely removed from the body. The hole allow blood to flow naturally from the left chamber to the right, lowering pressure on the left and increasing pressure on the right. This could drastically improve quality of life, keep patients independent and out of the hospital.

Current treatments for congestive heart failure include diuretics, but that medication has serious side effects that include kidney failure. A stent can also be inserted to create a passageway between the left and right atria, but carry the risk of blood clots and stroke. Alleviant Medical has developed an innovative solution that could reduce the reliance on costly medications. Although creating a hole in the heart come with risks, it could dramatically improve quality of life for millions of patients around the world. And the device’s ability to pack the severed tissue down, safely removing it from the body, reduce or potentially even eliminate the risk of any particles causing a stroke. The treatment is expected to lift the burden of heart failure, relieve symptoms and reduce hospitalization rates, significantly increasing 5 year survival rates.

Alleviant Medical was founded in early 2017 and has since gained much attention and won multiple awards. The startup has been part of the Rice Business Plan Competition, UMass Lowell’s M2D2 $100K Challenge, MassChallenge, Medtech Innovator and Texas Medical Center’s TMCx medical device accelerator. They have already developed a fully functional prototype and performed animal studies and is currently seeking seed financing to finalize design.